Investing.com - TD Cowen initiated coverage on Vor Biopharma, Inc. (NASDAQ:VOR) with a Buy rating on Wednesday, citing the potential of the company’s telitacicept therapy. The stock, currently trading ...

Vor Bio did not engage a placement agent for this transaction. In other recent news, Vor Biopharma Inc. announced a repricing of certain stock options for its employees and executives. The exercise ...

BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it has entered into a ...

Grand Slam Track, the league fronted by sprinting great Michael Johnson that offered six-figure prize money for top runners, has filed for bankruptcy after canceling its final event and failing to pay ...

In recent months, Vor Biopharma closed a US$424.83 million shelf registration, repriced employee stock options, and reported positive late-stage clinical data for its autoimmune drug candidate ...

Fintel reports that on December 9, 2025, JP Morgan initiated coverage of Vor Biopharma (NasdaqGS:VOR) with a Overweight recommendation. Analyst Price Forecast Suggests 388.04% Upside As of December 6, ...

Scientists used tiny new sensors to follow the insects on journeys that take thousands of miles to their winter colonies in Mexico. Scientists used tiny new sensors to follow the insects on journeys ...

Vor Biopharma shares fell sharply Tuesday in premarket trading after the company priced its $100 million offering below recent trading prices. Shares traded 31% lower ahead of the morning bell at ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Vor Biopharma ( (VOR)) has provided an ...

There is beauty and purity in a track-only car created by an automaker. Such creations are designed and engineered to serve one purpose exceedingly well without the need for parity against other cars.